Non-Surgical Therapeutic Strategies for Non-Melanoma Skin Cancers

被引:0
作者
Qingyu Zeng
Chengqian Chen
Diyan Chen
Guolong Zhang
Xiuli Wang
机构
[1] School of Medicine,Institute of Photomedicine, Shanghai Skin Disease Hospital
[2] Tongji University,undefined
来源
Current Treatment Options in Oncology | 2023年 / 24卷
关键词
Non-melanoma skin cancer; Basal cell carcinoma; Squamous cell carcinoma; Non-surgical therapy; Photodynamic therapy;
D O I
暂无
中图分类号
学科分类号
摘要
Non-melanoma skin cancer (NMSC) is a globally prevalent skin disease, with basal cell carcinoma and squamous cell carcinoma accounting for 99% of NMSC cases. While surgical excision is the most common approach, numerous non-surgical therapies have rapidly advanced in recent years. In cases of low-risk NMSC, alongside surgical excision, priority should be given to physical therapy and photodynamic therapy. Physical therapy modalities, exemplified by electrodessication and curettage, emerge as safe and efficacious alternatives. In juxtaposition, photodynamic therapy, albeit relatively more costly, assumes preference for patients exhibiting heightened cosmetic concerns owing to the scarring risks inherent to physical therapy and surgical excision. Notably, the combination of curettage and photodynamic therapy has exhibited remarkable efficacy in the treatment of nodular basal cell carcinoma. Additionally, for elderly patients who may be intolerant to stimulation, modified photodynamic therapy offers an almost painless option. When surgery is unavoidable, photodynamic therapy can be a valuable adjunct, allowing for a more conservative surgical approach, either before or after the procedure. Radiotherapy holds a prominent role in comprehensive treatment strategies, especially for patients ineligible for surgical intervention or those with lesions precluding further surgical measures. In cases of NMSC exhibiting perineural invasion or lymphovascular involvement, adjunctive radiotherapy is advised; however, potential adverse effects necessitate careful consideration. For advanced NMSC cases where surgery and physical therapy fall short, immunotherapy provide viable solutions. Systemic therapy employing Hedgehog pathway inhibitors can be considered for patients with distant metastatic basal cell carcinoma, despite its low incidence, or individuals with locally advanced lesions who are not surgical candidates, or those encountering recurrences after resection and radiotherapy. However, close monitoring of disease progression and adverse reactions is crucial. In this evolving landscape of NMSC treatment, personalized and multidisciplinary approaches are key, ensuring optimal outcomes while prioritizing patient safety and satisfaction.
引用
收藏
页码:1978 / 1993
页数:15
相关论文
共 245 条
[21]  
Mohsin N(2022)Definitive weekly hypofractionated radiotherapy in cutaneous squamous cell carcinoma: response rates and outcomes in elderly patients unfit for surgery Int J Dermatol 61 911-2325
[22]  
Levin N(2023)Review: PD-L1 as an emerging target in the treatment and prevention of keratinocytic skin cancer Mol Carcinog 62 52-374
[23]  
Dreyfuss I(2022)Cemiplimab in cutaneous squamous cell carcinomas (SCC): an overview and a clinical case Oral Oncol 128 105847-941
[24]  
Frech F(2023)Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: a systemic review and meta-analysis Skin Res Technol 29 e13229-298
[25]  
Nouri K(2016)PD-1 Blockade with pembrolizumab in advanced merkel-cell carcinoma N Engl J Med 374 2542-9938
[26]  
Khandelwal AR(2022)Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSe NIVOLUMAB trial Eur J Cancer 177 103-363
[27]  
Echanique KA(2020)Current Research in melanoma and aggressive nonmelanoma skin cancer Facial Plast Surg 36 200-1393
[28]  
St John M(2021)Local Chemotherapy as an adjuvant treatment in unresectable squamous cell carcinoma: what do we know so far? Curr Oncol 28 2317-4339
[29]  
Nathan CA(2021)Case report: in situ vaccination by autologous CD16(+) dendritic cells and anti-PD-L 1 antibody synergized with radiotherapy to boost T cells-mediated antitumor efficacy in a psoriatic patient with cutaneous squamous cell carcinoma Front Immunol 12 752563-2179
[30]  
Malvehy J(2016)New perspectives in the pharmacological treatment of non-melanoma skin cancer Curr Drug Targets 17 353-740